A multicenter, prospective clinical study demonstrated statistically significant and clinically meaningful improvements in WOMAC pain, stiffness, and function scores following a single intra-articular injection of Arthrosamid®. Sustained benefit was reported at 3 years, with extended follow-up data demonstrating durability up to 5 years.

• Holsgaard-Larsen A, et al. Long-term efficacy of intra-articular polyacrylamide hydrogel for knee osteoarthritis.
• Osteoarthritis and Cartilage. Presented at OARSI World Congress; follow-up data reported through 5 years.

The ROSA randomized trial compared injectable polyacrylamide hydrogel with hyaluronic acid in patients with knee osteoarthritis. Results demonstrated comparable or superior reductions in pain and improvements in function for Arthrosamid®, with sustained outcomes observed through 12 months following a single injection.

• Boffa A, et al. A prospective randomized comparison of polyacrylamide hydrogel versus hyaluronic acid for the treatment of knee osteoarthritis. Osteoarthritis and Cartilage. 2021.

A mechanistic clinical study evaluating Arthrosamid reported significant improvements in WOMAC and KOOS scores at 3, 6, and 12 months, with an overall responder rate of approximately 76% at 6 months. Synovial fluid analysis suggested a localized anti-inflammatory effect in clinical responders.

• Lind M, et al. Clinical and mechanistic outcomes following intra-articular polyacrylamide hydrogel injection for knee osteoarthritis. ISAKOS Biennial Congress Abstract, 2021.

A systematic review of clinical studies evaluating polyacrylamide hydrogel injections for knee osteoarthritis identified statistically significant improvements in pain and function lasting up to 24 months, with a favorable safety profile and low incidence of serious adverse events.

• Kjølstad G, et al. Injectable polyacrylamide hydrogel for knee osteoarthritis: a systematic review. Medical Research Archives. 2022;10(6).

Disclaimer: The information contained in this document is provided for educational purposes only and is intended to summarize selected clinical evidence relating to Arthrosamid®. Arthrosamid injections are offered at CMI as a private-pay medical service and are not insured by provincial health plans. Individual patient outcomes may vary. This document does not constitute medical advice and should not replace individualized assessment, diagnosis, or treatment recommendations by a qualified physician. Patients should discuss potential benefits, risks, alternatives, and suitability with their treating clinician prior to proceeding with treatment.